title: Prevention of adverse pregnancy outcomes with low-dose ASA in early pregnancy: new perspectives for future randomized trials.
abstract: Recent evidence suggests that treatment with low-dose acetylsalicylic acid (ASA) started early in pregnancy could prevent preeclampsia and intrauterine growth restriction (IUGR), two complications involving placental dysfunction. Preterm birth could also potentially be prevented, suggesting that it could share mechanisms of disease with preeclampsia and intrauterine growth restriction. Because there is new evidence that placental dysfunction can be predicted as early as in the first trimester, we argue that there is a need for randomized controlled trials of low-dose ASA for the prevention of preeclampsia, IUGR, and possibly preterm birth among nulliparous women with early indicators of placental dysfunction.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, Quebec QC; Centre de Recherche du Centre Hospitalier Universitaire de Québec (CRCHUQ), Quebec QC.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Bujold
authors.affiliation: Centre de Recherche du Centre Hospitalier Universitaire de Québec (CRCHUQ), Quebec QC; Department of Social and Preventive Medicine, Faculty of Medicine, Université Laval, Quebec QC.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Tapp
authors.affiliation: Department of Obstetrics and Gynecology, CHU Hôpital Sainte-Justine, Faculty of Medicine, Université de Montréal, Montreal QC.
authors.forename: Francois
authors.initials: F
authors.lastname: Audibert
authors.affiliation: Department of Pharmacy, CHU Hôpital Sainte-Justine, Faculty of Medicine, Université de Montréal, Montreal QC.
authors.forename: Ema
authors.initials: E
authors.lastname: Ferreira
authors.affiliation: Department of Medical Biology, Faculty of Medicine, Université Laval, Quebec QC.
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Forest
authors.affiliation: Departments of Medicine and of Obstetrics and Gynecology, Faculty of Medicine, Université de Montréal, Montreal QC.
authors.forename: Evelyne
authors.initials: E
authors.lastname: Rey
authors.affiliation: Department of Obstetrics and Gynecology, CHU Hôpital Sainte-Justine, Faculty of Medicine, Université de Montréal, Montreal QC.
authors.forename: William D
authors.initials: WD
authors.lastname: Fraser
authors.affiliation: Department of Obstetrics and Gynecology, CHU Hôpital Sainte-Justine, Faculty of Medicine, Université de Montréal, Montreal QC.
authors.forename: Nils
authors.initials: N
authors.lastname: Chaillet
authors.affiliation: Department of Medical Biology, Faculty of Medicine, Université Laval, Quebec QC.
authors.forename: Yves
authors.initials: Y
authors.lastname: Giguère
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005317:Fetal Growth Retardation / Q000517:prevention & control*; D006801:Humans; D018579:Patient Selection; D011225:Pre-Eclampsia / Q000517:prevention & control*; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin